Delcath Systems 株価情報 (NASDAQ: DCTH)

Delcath Systems (NASDAQ:DCTH) 株価情報

Delcath Systems

Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.

Delcath Systems Inc

News

DCTH

Delcath Systems Says Updated National Comprehensive Cancer Network Guidelines Now Include HEPZATO KIT As A Category 2A For Patients With Hepatic-Dominant Uveal Melanoma

Craig-Hallum analyst Chase Knickerbocker maintains Delcath Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCTH#NASDAQ">DCTH</a>) with a Buy and raises the price target from $18 to $21.

Price Target

Analyst Ratings

Craig-Hallum Maintains Buy on Delcath Systems, Raises Price Target to $21

In the latest quarter, 4 analysts provided ratings for Delcath Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCTH#NASDAQ">DCTH</a>), showcasing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $21.75, with a high estimate of $22.00 and a low estimate of $21.00. This current average is unchanged from the previous average price target. 
<img src="https://www.benzinga.com/files/images/story/2025/1736859655_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The analysis of recent analyst actions sheds light on the perception of Delcath Systems by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>John Newman</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$21.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.00</td>
<td>$22.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Delcath Systems. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Delcath Systems compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Delcath Systems's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Delcath Systems's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/DCTH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Delcath Systems analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Delving into Delcath Systems's Background</h2>
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
<h3>Delcath Systems: Financial Performance Dissected</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Delcath Systems's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 2480.65% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Delcath Systems's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 16.64%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Delcath Systems's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 29.21%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Delcath Systems's ROA stands out, surpassing industry averages. With an impressive ROA of 5.68%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.36, Delcath Systems adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>What Are Analyst Ratings?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Delcath Systems's Future

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth reiterates Delcath Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCTH#NASDAQ">DCTH</a>) with a Buy and maintains $22 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Delcath Systems, Maintains $22 Price Target

WIIM

Delcath Systems shares are trading higher after the company announced Q4 revenue results.

Fourth Quarter Revenue Approximately $15.1 Million and Full Year Total Revenue Approximately $37.2 Million
Delcath Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCTH#NASDAQ">DCTH</a>) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced preliminary financial results for the fourth quarter and year-ended December 31, 2024.
Preliminary Fourth Quarter and Full-Year 2024 Financial Results (unaudited)
<ul>
<li>Total fourth quarter and full year revenue expected to be approximately $15.1 million and $37.2 million, respectively</li>
<li>HEPZATO KIT&#x2122; fourth quarter and full year revenue expected to be approximately $13.7 million and $32.3 million, respectively</li>
<li>CHEMOSAT&#xAE; fourth quarter and full year revenue expected to be approximately $1.4 million and $4.9 million, respectively</li>
<li>Gross margins expected to be in the 80%-85% range</li>
<li>As of December 31, 2024, the Company had approximately $53.2 million of cash, cash equivalents and short-term investments and no debt</li>
</ul>
Final financial results for the fourth quarter and full year 2024 and a detailed business update will be provided during Delcath's annual financial results release and investor call scheduled for March 6, 2025.

Guidance

Delcath Systems Announces Q4 2024 Revenue At $15.1M, Full Year At $37.2M; HEPZATO Kit At $13.7M In Q4, $32.3M Annually; Gross Margins Between 80%-85%; $53.2M Cash And No Debt As Of Year-End 2024

U.S. stock futures were lower this morning, with the Dow futures falling over 100 points on Thursday.
Shares of MicroStrategy Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) fell sharply in today's pre-market trading following the company's announcement to issue more shares to finance additional Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) acquisitions. This move aligns with MicroStrategy's ongoing strategy to <a href="https://www.benzinga.com/quote/MSTR">bolster its Bitcoin reserves</a>.
MicroStrategy shares fell 3.5% to $345.65 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>NeuroPace, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NPCE#NASDAQ">NPCE</a>) shares dipped 10.1% to $10.01 in pre-market trading.</li>
<li>Delcath Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCTH#NASDAQ">DCTH</a>) declined 10% to $10.21 in pre-market trading.</li>
<li>Design Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSGN#NASDAQ">DSGN</a>) fell 8.6% to $5.80 in pre-market trading.</li>
<li>Cullinan Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGEM#NASDAQ">CGEM</a>) fell 8.6% to $11.21 in pre-market trading.</li>
<li>SunCoke Energy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SXC#NYSE">SXC</a>) dipped 8.2% to $9.90 in pre-market trading.</li>
<li>Gray Television, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GTN#NYSE">GTN</a>) fell 5.9% to $2.8505 in pre-market trading.</li>
<li>Portland General Electric Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/POR#NYSE">POR</a>) slipped 2.5% to $42.69 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42669200/wall-streets-most-accurate-analysts-give-their-take-on-3-utilities-stocks-with-over-4-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Utilities Stocks With Over 4% Dividend Yields</a></li>
</ul>

Pre-Market Outlook

Markets

Movers

Trading Ideas

$BTC

CGEM

DSGN

MSTR

NPCE

MicroStrategy, Portland General Electric And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Shares of Zoomcar Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZCAR#NASDAQ">ZCAR</a>) rose sharply in today's pre-market trading after it reported a 43% year-on-year growth in bookings for November 2024, primarily driven by increased wedding <a href="https://www.benzinga.com/quote/ZCAR/news">season demand</a>.
Zoomcar shares jumped 142% to $3.46 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>SciSparc Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRC#NASDAQ">SPRC</a>) gained 161% to $0.5775 in pre-market trading. SciSparc said AutoMax received its first shipment of vehicles manufactured by Anhui Jianghuai Automobile Group.</li>
<li>Millennium Group International Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGIH#NASDAQ">MGIH</a>) gained 153% to $3.8800 in pre-market trading after gaining 10% on Tuesday.</li>
<li>Color Star Technology Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADD#NASDAQ">ADD</a>) rose 94% to $4.20 in pre-market trading after the company announced a prominent member of the UAE&#8217;s royal family, has joined the company as an independent director.</li>
<li>SMX (Security Matters) Public Limited Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMX#NYSE">SMX</a>) shares jumped 69.3% to $0.3690 in pre-market trading.</li>
<li>reAlpha Tech Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRE#NASDAQ">AIRE</a>) gained 48% to $2.04 in pre-market trading after jumping around 10% on Tuesday.</li>
<li>Lichen China Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LICN#NASDAQ">LICN</a>) rose 35.7% to $0.2851 in pre-market trading after gaining around 24% on Tuesday.</li>
<li>SES AI Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SES#NYSE">SES</a>) gained 36.3% to $0.9689 in pre-market trading after surging around 36% on Tuesday.</li>
<li>China Yuchai International Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CYD#NYSE">CYD</a>) gained 25.8% to $12.32 in pre-market trading after gaining more than 5% on Tuesday.</li>
<li>SOBR Safe, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOBR#NASDAQ">SOBR</a>) rose 17.8% to $1.12 in pre-market trading after falling around 8% on Tuesday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Hour Loop, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOUR#NASDAQ">HOUR</a>) shares tumbled 30.5% to $3.0600 in pre-market trading after jumping 203% on Tuesday.</li>
<li>Carbon Revolution Public Limited Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CREV#NASDAQ">CREV</a>) fell 28.8% to $6.52 in pre-market trading. Carbon Revolution shares jumped 135% on Tuesday after the company announced it has reached an agreement with OIC for a further $25 million in financing to support the ongoing liquidity of the business.</li>
<li>SaverOne 2014 Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVRE#NASDAQ">SVRE</a>) declined 25.7% to $1.12 in pre-market trading after jumping around 63% on Tuesday.</li>
<li>Baosheng Media Group Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BAOS#NASDAQ">BAOS</a>) fell 25.7% to $5.26 in today's pre-market trading after jumping 310% on Tuesday.</li>
<li>Meiwu Technology Company Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WNW#NASDAQ">WNW</a>) shares dipped 25.1% to $1.64 in pre-market trading. Meiwu Technology regained compliance with Nasdaq Listing Rule, which requires ordinary shares to maintain minimum bid price.</li>
<li>Luokung Technology Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LKCO#NASDAQ">LKCO</a>) dipped 21.1% to $1.3500 in pre-market trading after gaining over 4% on Tuesday.</li>
<li>TCTM Kids IT Education Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCTM#NASDAQ">TCTM</a>) shares fell 21.1% to $0.5979 in pre-market trading.</li>
<li>Brera Holdings PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BREA#NASDAQ">BREA</a>) fell 18.1% to $0.8190 in pre-market trading after gaining over 42% on Tuesday.</li>
<li>NeuroPace, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NPCE#NASDAQ">NPCE</a>) shares fell 10.1% to $10.01 in pre-market trading.</li>
<li>Delcath Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCTH#NASDAQ">DCTH</a>) fell 10% to $10.21 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42669200/wall-streets-most-accurate-analysts-give-their-take-on-3-utilities-stocks-with-over-4-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Utilities Stocks With Over 4% Dividend Yields</a></li>
</ul>

AIRE

BAOS

BREA

CREV

HOUR

LICN

LKCO

MGIH

SOBR

SPRC

SVRE

TCTM

ZCAR

Why Zoomcar Shares Are Trading Higher By Around 142%; Here Are 20 Stocks Moving Premarket

Delcath Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCTH#NASDAQ">DCTH</a>), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that the U.S. Food and Drug Administration (FDA) has completed its 30-day review of the Company's Investigational New Drug (IND) application for a Phase 2 clinical trial evaluating HEPZATO&#x2122; in combination with standard of care (SOC) for liver-dominant metastatic colorectal cancer (mCRC). With the FDA's review complete, Delcath is now authorized to initiate patient enrollment.
The Phase 2 trial will evaluate the safety and efficacy of HEPZATO in combination with trifluridine-tipiracil and bevacizumab compared to trifluridine-tipiracil and bevacizumab alone in patients with liver-dominant mCRC receiving third-line treatment. Approximately 90 patients will be enrolled in this randomized, controlled trial. The study will take place at more than 20 sites across the United States and Europe, with patient enrollment expected to begin in the second half of 2025. The trial's primary endpoint, hepatic progression-free survival (hPFS), is anticipated to read out by the end of 2027, while overall survival (OS), a secondary endpoint, is expected in 2028.
The company estimates that the total addressable market (TAM) for liver-dominant mCRC receiving third-line treatment is between 6,000 and 10,000 patients annually in the United States. This market includes patients who present with significant liver disease burden, with liver-dominant status determined through radiological and clinical criteria. By targeting this patient population, Delcath aims to provide a novel treatment option for those with limited therapeutic alternatives.

Biotech

General

Delcath Systems Announces FDA Clearance Of IND Application For Phase 2 Clinical Trial Of HEPZATO In Combination With Standard Of Care In Liver-Dominant Metastatic Colorectal Cancer

Delcath Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCTH#NASDAQ">DCTH</a>) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.23) by 73.91 percent. This is a 94.74 percent increase over losses of $(1.14) per share from the same period last year. The company reported quarterly sales of $11.20 million which beat the analyst consensus estimate of $10.46 million by 7.08 percent. This is a 2.48K percent increase over sales of $434.00 thousand the same period last year.

Earnings

Delcath Systems Q3 2024 GAAP EPS $(0.06) Beats $(0.23) Estimate, Sales $11.20M Beat $10.46M Estimate

Delcath Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCTH#NASDAQ">DCTH</a>) is set to give its latest quarterly earnings report on Friday, 2024-11-08. Here's what investors need to know before the announcement.
Analysts estimate that Delcath Systems will report an earnings per share (EPS) of $-0.22. 
The market awaits Delcath Systems's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Overview of Past Earnings</h3>
During the last quarter, the company reported an EPS missed by $0.12, leading to a 4.93% drop in the share price on the subsequent day.
Here's a look at Delcath Systems's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.36</td>
<td>-0.47</td>
<td>-0.51</td>
<td>-0.52</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.48</td>
<td>-0.45</td>
<td>-0.48</td>
<td>-1.14</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-5.0%</td>
<td>2.0%</td>
<td>10.0%</td>
<td>-24.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1731006227_0.png" alt="eps graph" />
<h3>Market Performance of Delcath Systems's Stock</h3>
Shares of Delcath Systems were trading at $10.94 as of November 06. Over the last 52-week period, shares are up 274.92%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analyst Insights on Delcath Systems</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Delcath Systems.
The consensus rating for Delcath Systems is Buy, derived from 2 analyst ratings. An average one-year price target of $21.5 implies a potential 96.53% upside.
<h3>Comparing Ratings Among Industry Peers</h3>
This comparison focuses on the analyst ratings and average 1-year price targets of Pulmonx, AngioDynamics and Zynex, three major players in the industry, shedding light on their relative performance expectations and market positioning.
<ul>
<li>The consensus outlook from analysts is an Buy trajectory for Pulmonx, with an average 1-year price target of $16.0, indicating a potential 46.25% upside.</li>
<li>Analysts currently favor an Buy trajectory for AngioDynamics, with an average 1-year price target of $13.33, suggesting a potential 21.85% upside.</li>
<li>Zynex is maintaining an Buy status according to analysts, with an average 1-year price target of $14.67, indicating a potential 34.1% upside.</li>
</ul>
<h3>Peers Comparative Analysis Summary</h3>
The peer analysis summary provides a snapshot of key metrics for Pulmonx, AngioDynamics and Zynex, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Delcath Systems</td>
<td>Buy</td>
<td>1468.89%</td>
<td>$6.25M</td>
<td>-146.09%</td>
</tr>
<tr>
<td>Pulmonx</td>
<td>Buy</td>
<td>15.39%</td>
<td>$15.03M</td>
<td>-14.50%</td>
</tr>
<tr>
<td>AngioDynamics</td>
<td>Buy</td>
<td>-14.22%</td>
<td>$36.72M</td>
<td>-6.36%</td>
</tr>
<tr>
<td>Zynex</td>
<td>Buy</td>
<td>0.10%</td>
<td>$39.79M</td>
<td>6.95%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Delcath Systems ranks first in revenue growth among its peers. It has the lowest gross profit margin. Delcath Systems has the lowest return on equity.
<h3>Delving into Delcath Systems's Background</h3>
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
<h3>Breaking Down Delcath Systems's Financial Performance</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Over the 3 months period, Delcath Systems showcased positive performance, achieving a revenue growth rate of 1468.89% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Delcath Systems's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -176.94%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Delcath Systems's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -146.09%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -39.25%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Delcath Systems's debt-to-equity ratio is below the industry average. With a ratio of 1.33, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<a href="https://www.benzinga.com/quote/DCTH/earnings">To track all earnings releases for Delcath Systems visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Uncovering Potential: Delcath Systems's Earnings Preview

4 analysts have shared their evaluations of Delcath Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCTH#NASDAQ">DCTH</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $22.5, with a high estimate of $25.00 and a low estimate of $21.00. This current average has not changed from the previous average price target. 
<img src="https://www.benzinga.com/files/images/story/2024/1729263675_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A clear picture of Delcath Systems's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>John Newman</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$21.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Sudan Loganathan</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$25.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.00</td>
<td>$22.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Delcath Systems. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Delcath Systems compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Delcath Systems's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Delcath Systems's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/DCTH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Delcath Systems analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About Delcath Systems</h2>
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
<h3>Delcath Systems: A Financial Overview</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Delcath Systems showcased positive performance, achieving a revenue growth rate of 1468.89% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Delcath Systems's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -176.94%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Delcath Systems's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -146.09%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Delcath Systems's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -39.25%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.33.
<h2>What Are Analyst Ratings?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Scoreboard: 4 Ratings For Delcath Systems

Canaccord Genuity analyst John Newman maintains Delcath Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCTH#NASDAQ">DCTH</a>) with a Buy and maintains $21 price target.

Canaccord Genuity Maintains Buy on Delcath Systems, Maintains $21 Price Target

Delcath Systems shares are trading higher after the company announced better-than-expected preliminary Q3 revenue results.

Delcath Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCTH#NASDAQ">DCTH</a>) sees Q3 sales of $11.200 million vs $9.45 million estimate.

Delcath Systems Sees Q3 2024 Preliminary Sales $11.200M vs $9.45M Est

Delcath Systems Highlights Presentation Of Data At ESMO 2024 Demonstrating Efficacy Of HEPZATO KIT For Metastatic Uveal Melanoma Subgroups

On CNBC's &#8220;Mad Money Lightning Round,&#8221; Jim Cramer said, &#8220;This is a very speculative situation,&#8221; when asked about ADMA Biologics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>). &#8220;Any time there's immunity-compromised patients, there's some <a href="https://www.benzinga.com/quote/ADMA">big money down the road,&#8221; he added.</a>
On Aug. 8, ADMA Biologics reported better-than-expected second-quarter financial results and raised its FY24 and FY25 revenue guidance above estimates. 
The company reported quarterly earnings of 13 cents per share which beat the analyst consensus estimate of 7 cents per share. The company reported quarterly sales of about $107.2 million which beat the analyst consensus estimate of $86.4 million.
&#8220;This is one of those situations that is very difficult,&#8221; Cramer on MP Materials Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MP#NYSE">MP</a>). &#8220;If they don't pull out of the tailspin of losses, then it just doesn't matter.&#8221;
On July 25, Marine Prods posted better-than-expected sales for its second quarter. Marine Prods reported quarterly earnings of 14 cents per share which met the analyst consensus estimate. The company reported quarterly sales of $69.55 million which beat the analyst consensus estimate of $65.35 million.
When asked about Delcath Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCTH#NASDAQ">DCTH</a>), he said, &#8220;There's no investing. At this point, it is speculating.&#8221;
On Aug. 28, Delcath Systems announced positive results from independent study on liver-directed therapy for uveal melanoma patients.
Price Action:
<ul>
<li>ADMA Biologics shares fell 0.1% to settle at $17.22 on Thursday.</li>
<li>MP Materials shares gained 3.2% to close at $12.90.</li>
<li>Delcath Systems shares gained 1.2% to close at $10.77.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/08/40624754/top-2-materials-stocks-that-are-ticking-portfolio-bombs">Top 2 Materials Stocks That Are Ticking Portfolio Bombs</a></li>
</ul>
Image: Shutterstock

Long Ideas

Media

ADMA

'This Is A Very Speculative Situation,' Jim Cramer On ADMA Biologics

Delcath Systems Announces Results from Independent Study On Liver-Directed Therapy for Uveal Melanoma Patients

Press Releases

Delcath Systems to Participate in Upcoming Investor Conferences

Delcath Systems Reports Third Quarter 2024 Results and Business Highlights

Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal Cancer

Clear Street Launches Healthcare & Biotechnology Equity Research

Delcath Systems Announces Additional $16.3 Million in Funding From Series E and E1 Warrant Exercises

Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results

Delcath Systems to Participate at the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Delcath Systems Announces Update to National Comprehensive Cancer Network Clinical Practice Guidelines for the Treatment of Metastatic Uveal Melanoma

Comments

Delcath Systems

ニュース

パートナーシップ

ベンジンガ・グローバル